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Abstract
Malignant carcinomas that recur following therapy are typically de-differentiated and multidrug resistant (MDR). De-differentiated
cancer cells acquire MDR by up-regulating reactive oxygen species (ROS)–scavenging enzymes and drug efflux pumps, but how
these genes are up-regulated in response to de-differentiation is not known. Here, we examine this question by using global
transcriptional profiling to identify ROS-induced genes that are already up-regulated in de-differentiated cells, even in the absence
of oxidative damage. Using this approach, we found that the Nrf2 transcription factor, which is the master regulator of cellular
responses to oxidative stress, is preactivated in de-differentiated cells. In de-differentiated cells, Nrf2 is not activated by oxidation but
rather through a noncanonical mechanism involving its phosphorylation by the ER membrane kinase PERK. In contrast,
differentiated cells require oxidative damage to activate Nrf2. Constitutive PERK-Nrf2 signaling protects de-differentiated cells from
chemotherapy by reducing ROS levels and increasing drug efflux. These findings are validated in therapy-resistant basal breast
cancer cell lines and animal models, where inhibition of the PERK-Nrf2 signaling axis reversed the MDR of de-differentiated cancer
cells. Additionally, analysis of patient tumor datasets showed that a PERK pathway signature correlates strongly with chemotherapy
resistance, tumor grade, and overall survival. Collectively, these results indicate that de-differentiated cells up-regulate MDR genes
via PERK-Nrf2 signaling and suggest that targeting this pathway could sensitize drug-resistant cells to chemotherapy.
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Introduction
Multidrug resistance (MDR) is the primary obstacle to treating
malignant tumors [1]. Cancer cells develop MDR by overex-
pressing antioxidant enzymes that neutralize the reactive oxygen
species (ROS) required for chemotherapy toxicity or by up-
regulating drug efflux pumps [2,3]. In many cancers, these MDR
mechanisms are up-regulated by mutation or amplification of
genes encoding antioxidant enzymes or drug efflux pumps. Many
other cancers, however, up-regulate these genes through non-
mutational mechanisms that remain poorly understood.
One nonmutational mechanism by which cancer cells acquire
MDR is de-differentiation. De-differentiation is a well-established
marker of poor prognosis tumors and can occur when differen-
tiated cells are induced into a more primitive stem-cell–like state
[4–6]. One mechanism by which both cancerous and noncancer-
ous cells can be de-differentiated is through induction of an
epithelial-to-mesenchymal transition (EMT) [7–14]. De-differen-
tiated cancer cells generated by EMT and cancer stem-like cells
are both resistant to a wide range of chemotherapies [15–19].
Conversely, cells experimentally induced to differentiate are more
sensitive to chemotherapies [20–23]. Although de-differentiation is
known to up-regulate MDR mechanisms as described above, how
this occurs is poorly understood.
In this article, we examine this question by employing a global
transcriptional profiling approach to identify ROS-induced genes
that are preactivated in de-differentiated cells. Many of these
genes—which are activated in de-differentiated cells even in the
absence of oxidative damage—are regulated by a single signaling
pathway. We further show that this pathway is critical for de-
differentiated cells to resist chemotherapies.
Results
To study the effects of differentiation state on MDR, we used
isogenic pairs of human breast epithelial cells (HMLE) that were
either differentiated and expressed a control vector, or de-
differentiated through induction of an EMT—achieved by
expressing the Twist transcription factor [24,25]. These de-
differentiated HMLE-Twist cells were more resistant to the
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chemotherapy drugs Paclitaxel (Tax) and Doxorubicin (Dox) than
differentiated HMLE-shGFP cells, consistent with prior reports
(1.56 and 2.56, respectively; Figure 1a) [26,27]. To determine
how Twist-induced de-differentiation caused MDR, we assessed
whether known mechanisms were up-regulated in these cells.
Twist overexpression significantly increased efflux pump activity
(Figure 1b) and lowered ROS levels—both basal and induced by
the oxidizer menadione or Dox (Figure 1c,d) [28]. Additionally,
HMLE-Twist cells displayed significantly lower amounts of lipid
peroxidation compared to HMLE-shGFP cells (Figure 1e). As a
measure of overall reducing capacity of the cells, we also show that
HMLE-Twist cells had a greater pool of reduced glutathione,
which could be maintained even in the presence of menadione
(Figure 1f). Finally, Twist overexpression led to a significant
increase in expression of enzymes involved in ROS metabolism:
superoxide dismutase 1 (SOD1) and catalase (CAT) (Figure 1g).
We suspected that these MDR mechanisms were up-regulated
through a normal regulator of the cellular antioxidant response.
To identify putative regulators, we transcriptionally profiled
HMLE-shGFP and HMLE-Twist cells treated with vehicle or
menadione (Table S1). In the absence of oxidative stress, 1,694
genes were differentially expressed between the two cell types,
several of which were ROS and efflux-related genes (Tables S2
and S3). Treatment with menadione induced the expression of 181
and 170 genes in HMLE-shGFP and HMLE-Twist cells,
respectively, with 44 genes being commonly induced in both cell
types (Table S4; hypergeometric test, p value,1.0610210). Of the
181 genes induced by menadione in HMLE-shGFP cells, 54 were
already up-regulated in HMLE-Twist cells in the absence of
treatment (Table S5; hypergeometric test, p value,1.0610210,
Figure 1h). Of these 54 genes, 38 were uniquely induced in
HMLE-shGFP but not HMLE-Twist cells treated with menadi-
one. This suggests that some oxidative stress response genes are
‘‘preactivated’’ in de-differentiated HMLE-Twist cells.
The most significantly preactivated gene in HMLE-Twist cells
was heme oxygenase 1 (HMOX-1)—expressed at 8-fold higher
levels in HMLE-Twist cells compared to HMLE-shGFP cells and
induced 22-fold in differentiated cells treated with menadione.
HMOX-1 is a well-characterized enzyme involved in the
metabolism of heme, but is also a major target of master
antioxidant regulator Nrf2 [29–31]. The Nrf2 transcription factor
activates an arsenal of antioxidant genes and ABC transporters,
and its up-regulation is associated with acquired MDR [32–35].
To test whether Nrf2 might be basally active in HMLE-Twist cells,
but not HMLE-shGFP cells, we examined Nrf2 target gene
expression. Of 1,013 Nrf2 direct-target genes, a significant
number—142 genes—were up-regulated in HMLE-Twist cells
compared to HMLE-shGFP cells in the absence of oxidative stress
(Table S6; hypergeometric test, p value,1.0610210) [36].
Further, 7 of the 54 oxidative stress response genes ‘‘preactivated’’
in HMLE-Twist cells were Nrf2 direct-target genes, representing a
significant enrichment over the number predicted by random
chance (Table S5; hypergeometric test, p value = 4.961025,
Figure 1h). To confirm Nrf2 activation in HMLE-Twist cells, we
assessed its subcellular localization by immunofluorescence. In
HMLE-shGFP cells, Nrf2 was sequestered in the cytoplasm and
translocated to the nucleus when cells were treated with
menadione (Figure 1i). In HMLE-Twist cells, however, Nrf2 was
constitutively in the nucleus, and treatment with menadione only
modestly increased its nuclear accumulation (Figure 1i). These
findings demonstrate that Nrf2 is constitutively active in de-
differentiated HMLE-Twist cells—even in the absence of exoge-
nous stress.
We next examined why Nrf2 was constitutively active in
HMLE-Twist cells, even though basal ROS levels are low.
Although ROS activate Nrf2 by oxidation, it can also be activated
in the absence of oxidative stress by several kinases [37–39]. In
particular, Nrf2 is directly phosphorylated and activated by the
ER-membrane kinase PERK, which is canonically activated under
conditions of ER stress as part of the unfolded protein response
(UPR) [40–42]. In this context, PERK relieves ER stress by
slowing protein translation through phosphorylation of eiF2a. We
have recently shown that PERK is also activated upon EMT-
induced de-differentiation—even in the absence of overt ER stress
[43]. Consistent with this, we found that PERK is constitutively
phosphorylated in HMLE-Twist cells, but not in HMLE-shGFP
cells, and inhibition of PERK with a small-molecule inhibitor
blocked its phosphorylation (Figure 2a) [44]. To understand if
PERK controls constitutive Nrf2 activation in HMLE-Twist cells,
we assessed Nrf2 localization following PERK inhibition. We
found that inhibition of PERK fully reversed the nuclear
localization of Nrf2 in HMLE-Twist cells, but did not prevent
oxidative stress-induced nuclear accumulation of Nrf2 in either
HMLE-shGFP or HMLE-Twist cells (Figure 2b). As a comple-
mentary approach to PERK inhibition and to rule out off-target
effects of the small-molecule PERK inhibitor, we also generated
cell lines in which PERK expression was stably inhibited by two
different shRNAs (Figure 2c). Inhibition of PERK by shRNA
significantly decreased Nrf2 nuclear localization in HMLE-Twist
cells, mirroring the results obtained with the small-molecule
PERK inhibitor (Figure 2d). Collectively, these results demon-
strate that Nrf2 nuclear localization is controlled by PERK in de-
differentiated HMLE-Twist cells.
To confirm that Nrf2 nuclear localization correlated with its
activation, we assessed Nrf2 target gene expression following
PERK inhibition. We found that PERK inhibition significantly
decreased HMOX-1 expression in HMLE-Twist cells, but did not
prevent induction of HMOX-1 in response to oxidative stress
(Figure 2e). Moreover, using microarray gene expression analyses,
we found that PERK inhibition decreased the expression of 58 of
the 142 Nrf2-target genes (41%) activated in HMLE-Twist cells
(Table S6). Amongst these PERK-Nrf2-target genes were ABC
transporters, enzymes involved in glutathione metabolism and
ROS buffering, and several proteins with known roles in drug
Author Summary
The development of multidrug resistance is the primary
obstacle to treating cancers. High-grade tumors that are
less differentiated typically respond poorly to therapy and
carry a much worse prognosis than well-differentiated low-
grade tumors. Therapy-resistant cancer cells often overex-
press antioxidants or efflux proteins that pump drugs out
of the cell, but how the differentiation state of cancer cells
influences these resistance mechanisms is not well
understood. Here we used genome-scale approaches and
found that the PERK kinase and its downstream target,
Nrf2—a master transcriptional regulator of the cellular
antioxidant response—are key mediators of therapy
resistance in poorly differentiated breast cancer cells. We
show that Nrf2 is activated when cancer cells de-
differentiate and that this activation requires PERK. We
further show that blocking PERK-Nrf2 signaling with a
small-molecule inhibitor sensitizes drug-resistant cancer
cells to chemotherapy. Our results identify a novel role for
PERK-Nrf2 signaling in multidrug resistance and suggest
that targeting this pathway could improve the respon-
siveness of otherwise resistant tumors to chemotherapy.
PERK-Nrf2 Signaling Confers Multidrug Resistance
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Figure 1. De-differentiated cells activate MDR and Nrf2 in the absence of oxidative or chemotherapy stress. (a) Fraction of HMLE-
shGFP or HMLE-Twist cells surviving 3-d treatment with 2 nM Tax or 30 nM Dox, normalized to individual vehicle-treated controls. (b) Flow cytometry
quantification of MDR1-mediated efflux ability. HMLE-shGFP or HMLE-Twist cells were loaded with cell-permeable DiOC2(3)-dye and efflux ability
measured by loss of fluorescent signal after 1.5 h (efflux) compared to the loading control. (c) Fluorescent microscopy images of relative cellular ROS
levels using the mitochondrial superoxide (MitoSOX) probe (red channel) or general oxidative stress (CellROX) probe (red channel) and cell nuclei
labeled with DAPI (blue channel). (d) Flow cytometry quantification of MitoSOX fluorescence relative to individual vehicle-treated controls. Cells were
treated with 40 mM menadione, 1 mM Dox, 1 mM Tax, or DMSO for 2 h prior to analysis. (e) Fluorescent microscopy images of relative lipid
peroxidation levels (green channel) and cell nuclei labeled with DAPI (blue channel). Indicated cells were treated with 100 mM cumene hydroperoxide
or DMSO for 2 h prior to analysis. (f) Relative amounts of reduced (GSH) to oxidized (GSSG) glutathione measured by luminescence-based assay.
Indicated cells were treated with 40 mM menadione or DMSO for 2 h prior to analysis. Each sample is normalized to HMLE-shGFP DMSO control. (g)
Western blot analysis of SOD1, CAT, and b-actin. (h) Overlap of genes .2-fold up-regulated in differentiated cells treated with 40 mM menadione
(ROS) for 2 h compared to corresponding DMSO control (blue circle), and de-differentiated cells compared to differentiated cells in the absence of
treatment (purple circle). (i) Immunofluorescence microscopy images of Nrf2 localization upon treatment with 40 mM menadione or DMSO for 2 h.
Nrf2 protein was indirectly labeled with a secondary Alexa Fluor 488 antibody (green channel) and cell nuclei labeled with DAPI (blue channel). *p,
0.05. Data are presented as mean 6 SEM.
doi:10.1371/journal.pbio.1001945.g001
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Figure 2. Nrf2 is constitutively activated by PERK in de-differentiated cells. (a) Immunofluorescence microscopy images of phospho-PERK
(pPERK) upon treatment with 40 nM thapsigargin (Tg) for 2 h or 1 mM PERK inhibitor (PERKi) for 2 d. pPERK protein was indirectly labeled with a
secondary Alexa Fluor 488 antibody (green channel) and cell nuclei labeled with DAPI (blue channel). (b) Immunofluorescence microscopy images of
Nrf2 localization upon treatment with 1 mM PERKi or DMSO for 2 d, followed by 40 mM menadione or DMSO for 2 h. Nrf2 protein was indirectly
labeled with a secondary Alexa Fluor 488 antibody (green channel) and cell nuclei labeled with DAPI (blue channel). (c) Quantitative RT-PCR analysis
of PERK gene expression in cells stably expressing control (shLuc) or PERK-specific shRNA (shPERK 1 and shPERK 2). Expression is shown normalized to
the HMLE-Twist shLuc sample. (d) Immunofluorescence microscopy images of Nrf2 localization in cell lines with stable knockdown of PERK compared
PERK-Nrf2 Signaling Confers Multidrug Resistance
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resistance. These findings confirm that the exit of Nrf2 from the
nucleus correlates with down-regulation of its target genes.
PERK has previously been shown to bind to, directly
phosphorylate, and activate Nrf2, though the exact phosphoryla-
tion sites have not yet been determined [42]. To show that PERK
directly regulates Nrf2 in our system, we performed PERK
immunoprecipitation followed by western blot with a Nrf2-specific
antibody—which confirmed that PERK and Nrf2 directly interact
in HMLE-Twist cells (Figure 2f). We also immunoprecipitated
Nrf2 in either the presence or absence of the PERK inhibitor,
which demonstrated that Nrf2 phosphorylation was markedly
reduced by PERK inhibition (Figure 2g). These data, combined
with our finding that inhibiting PERK decreases nuclear
accumulation of Nrf2, suggest that PERK directly interacts with
Nrf2 to mediate its nuclear translocation and activation.
We next tested whether inhibition of PERK would eliminate
MDR phenotypes associated with HMLE-Twist cells. PERK
inhibition caused a 45% increase in mitochondrial ROS levels in
HMLE-Twist cells, but did not affect HMLE-shGFP cells (Figure 3a).
PERK inhibition also significantly increased lipid peroxidation in
HMLE-Twist cells, but not in HMLE-shGFP cells (Figure 3b).
PERK inhibition compromised ROS buffering—cells pretreated
with the PERK inhibitor produced 25%–55% more ROS than
vehicle-treated cells (Figure 3c). Additionally, PERK inhibition led to
a significant decrease in the expression of ROSmetabolizing enzymes
SOD1 and CAT (Figure 3d). Lastly, inhibition of PERK signaling
reduced the percentage of high-effluxing HMLE-Twist cells by 50%
and did not affect efflux in HMLE-shGFP cells (Figure 3e). Together
these results demonstrate that a simple change in differentiation state
confers MDR phenotypes, and these are mediated by constitutive
PERK signaling.
To understand how this applies in the context of cancer, we
expanded our analyses to include several luminal and basal-like
breast cancer cell lines, which represent epithelial-like/differenti-
ated and mesenchymal-like/de-differentiated cells, respectively
[45]. Previous work has shown that PERK is preferentially
activated in basal compared to luminal cell lines [43]. Consistent
with our results in the HMLE system, basal breast cancer cells had
lower overall ROS than luminal cells, and addition of the PERK
inhibitor caused a dramatic increase in ROS levels in basal cells
but not luminal cells (Figure 3f). Likewise, inhibition of PERK
caused a 25% reduction in the ratio of reduced to oxidized
glutathione in only the basal cell lines, indicative of decreased
ROS buffering (Figure 3g). This indicates that PERK contributes
to the enhanced oxidative stress buffering ability of both
noncancerous and cancerous de-differentiated cells.
In order to affect chemotherapy resistance, we rationalized that
PERK inhibition would need to occur prior to chemotherapy
exposure to allow time for reversal of MDR phenotypes
(Figure 4a). Pretreatment with the PERK inhibitor greatly
sensitized both HMLE-Twist and HMLE-shGFP cells to subse-
quent treatment with Tax and Dox—the number of surviving cells
was reduced significantly in both cell types (Figure 4b). Treatment
with a ROS-scavenging agent n-acetyl cysteine (NAC) was able to
rescue this decreased survival, indicating that PERK pathway
activation contributes to chemotherapy resistance in significant
part via ROS buffering (Figure 4c,d) [46]. We also utilized a small
molecule—oltipraz—capable of inducing Nrf2 activation (Figur-
e 4e,f) [47]. Activation of Nrf2 significantly rescued PERK-
dependent decreases in cell survival. To rule out the possibility that
off-target effects of oltipraz were responsible for this effect, we
performed the same rescue experiment in cells with stable Nrf2
knockdown achieved by two independent shRNAs. When Nrf2
was inhibited, oltipraz was no longer able to rescue the effects of
PERK inhibition, confirming that these effects were mediated by
Nrf2 (Figure 4g–i). These results indicate that PERK signaling
through Nrf2 is responsible for the acquisition of MDR.
These results prompted us to test the effect of PERK inhibition in
vivo, utilizing xenografted tumors derived from therapy-resistant
basal breast cancer cells. We utilized a treatment plan involving
cycles of pretreatment with the PERK inhibitor, followed imme-
diately by treatment with Dox. The combined treatment resulted in
significantly smaller tumors compared to single or mock treatments
(Figure 5a). To test if PERK inhibition affected ROS buffering in
vivo, we harvested tumors from each of the four treatment groups
and measured the expression of the ROS-metabolizing enzyme
SOD1. We found that the Dox, PERK inhibitor, and combined
treatment groups all had significantly reduced expression of SOD1
compared to control tumors, with the dual-treated tumors having
the lowest expression (Figure 5b). Additionally, the combined
treatment group had the most necrotic cells compared to the other
treatment groups (Figure 5c).
We next adjusted the dosage schedule to highlight the
synergistic interactions between PERK inhibition and Dox
treatment and found that reducing the total dosage and frequency
of treatments further emphasized the sensitization effect—dual-
treated tumors were 4 times smaller than Dox-treated tumors and
.5 times smaller than PERK inhibitor or mock-treated groups
(Figure 5d). Although prior research has shown that PERK is
critical for tumor growth and angiogenesis [48–50], we found that
low-dose inhibition only minimally impacted tumor growth in the
absence of chemotherapy. To assess the in vivo effects on ROS
buffering, we measured the levels of reduced glutathione (GSH) in
tumors harvested from each treatment group. Dox, PERK
inhibitor, and combined treatment groups all had decreased levels
of GSH compared to the control group, with the dual-treated
tumors having the lowest amount (Figure 5e).
As an important control to demonstrate that the observed in vivo
results were not due to off-target effects of the PERK inhibitor, we
utilized xenografted tumors derived from luminal breast cancer
cells. Although treatment with Dox led to a reduction in tumor size,
inhibition of PERK did not provide any additive benefit in the
luminal tumors (Figure 5f). This confirms that the effects observed
in the basal breast cancer xenografts are not due to off-target effects
of the PERK inhibitor, as luminal cells—unlike basal cells—do not
constitutively activate PERK and do not significantly respond to
PERK inhibition. Together our results suggest that combining Dox
treatment with PERK inhibition compromises the ROS-buffering
capacity of basal-like breast cancer cells and sensitizes them to
chemotherapy-induced cell death.
To assess the clinical relevance of our findings, we analyzed
primary human breast tumor datasets. Utilizing two independent
to control knockdown cells. Nrf2 protein was indirectly labeled with a secondary Alexa Fluor 488 antibody (green channel) and cell nuclei labeled with
DAPI (blue channel). Quantification of the number of cells with nuclear versus cytoplasmic Nrf2 localization is shown below. One hundred cells were
analyzed per group, and the resulting ratio is normalized to the HMLE-shGFP shLuc group. (e) Western blot analysis of HMOX-1 and b-actin. HMLE-
shGFP or HMLE-Twist cells were treated with 1 mM PERKi or DMSO for 2 d, followed by 40 mM menadione or DMSO for 2 h prior to cell lysis. (f) PERK
or Nrf2-bound proteins were immunoprecipitated from HMLE-Twist cells, followed by immunoblotting for Nrf2. (g) Nrf2 immunoprecipitation
followed by Western blot analysis of pan-phosphorylation. HMLE-Twist cells were treated with 1 mM PERKi or DMSO for 2 d prior to analysis.
doi:10.1371/journal.pbio.1001945.g002
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Figure 3. PERK activates MDR mechanisms in de-differentiated cells. (a) Fluorescent microscopy images of cellular ROS levels using the
MitoSOX probe (red channel) and cell nuclei labeled with DAPI (blue channel). HMLE-shGFP or HMLE-Twist cells were treated with 1 mM PERKi or DMSO
for 2 d prior to imaging. Quantification per cell is shown on the right. Each group is normalized to the HMLE-Twist DMSO group. (b) Fluorescent
microscopy images of relative lipid peroxidation levels (green channel) and cell nuclei labeled with DAPI (blue channel). HMLE-shGFP or HMLE-Twist cells
were treated with 1 mM PERKi or DMSO for 2 d prior to imaging. Quantification per cell is shown on the right. Each group is normalized to the HMLE-
shGFP DMSO group. (c) Flow cytometry quantification of ROS buffering by measuring MitoSOX fluorescence relative to individual vehicle-treated
controls. HMLE-shGFP or HMLE-Twist cells were treated with 1 mM PERKi or DMSO for 2 d, followed by 40 mM menadione, 1 mM Dox, or DMSO for 2 h
prior to analysis. (d) Western blot analysis of SOD1, CAT, and b-actin. HMLE-shGFP or HMLE-Twist cells were treated with 1 mM PERKi or DMSO for 2 d
prior to cell lysis. (e) Flow cytometry was utilized to quantitate efflux ability of HMLE-shGFP or HMLE-Twist cells treated with 1 mM PERKi or DMSO for 5 d.
Results are shown as percentage of cells with the ability to efflux.50% of loaded DiOC2(3)-dye. (f) Fluorescent microscopy images of cellular ROS levels
in luminal and basal breast cancer cell lines using the MitoSOX probe as in (a). Each group is normalized to the MDA.MB.231 DMSO group. (g) Relative
amounts of reduced (GSH) to oxidized (GSSG) glutathione. Luminal and basal breast cancer cells were treated with 1 mM PERKi or DMSO for 2 d prior to
analysis. Each sample is normalized to the MCF7 DMSO group. *p,0.05. Data are presented as mean 6 SEM.
doi:10.1371/journal.pbio.1001945.g003
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Figure 4. Inhibition of PERK-Nrf2 signaling sensitizes de-differentiated cells to chemotherapy. (a) Schematic of treatment timing and
dosage for cell survival experiments described in (b–f). (b) Fraction of cells surviving 2 nM Tax or 30 nM Dox following pretreatment with 1 mM PERKi
or DMSO, normalized to individual vehicle-treated controls. (c and d) Fraction of cells surviving 30 nM Dox (c) or 2 nM Tax (d) following pretreatment
with 1 mM PERKi or DMSO and rescue with 3 mM NAC, normalized to individual vehicle-treated controls. (e and f) Fraction of cells surviving 30 nM
Dox (e) or 2 nM Tax (f) following pretreatment with 1 mM PERKi or DMSO and rescue with 25 mM Oltipraz, normalized to individual vehicle-treated
PERK-Nrf2 Signaling Confers Multidrug Resistance
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datasets (comprised of 413 patient tumors), we first tested for
correlations between the expression of PERK pathway genes and
genes associated with the basal subtype of breast cancer. We found
that a PERK gene expression signature correlated positively with a
basal breast cancer gene signature, suggesting that the PERK
signaling pathway is active in basal breast tumors (Figure 5g) [51].
As a negative control, an IRE1 gene expression signature did not
show a significant correlation (Figure 5g). Additionally, we found
that PERK pathway activity could stratify patient response to
therapy—85% of PERK-low tumors displayed complete or partial
response to therapy, compared to only 38% of PERK-high tumors
(Figure 5h). Finally, PERK pathway expression also correlated to
differentiation state and overall survival in invasive high-grade
glioma—tumors stratified into a PERK-high group were almost
exclusively poorly differentiated grade 4 GBM and had signifi-
cantly worse overall survival than the PERK-low group (Figur-
e 5i,j). These results highlight the relevance of our work in primary
tumors, and suggest that targeting PERK signaling may be
beneficial in highly aggressive and malignant tumor types.
Discussion
These findings identify PERK-Nrf2 signaling as one mechanism
by which de-differentiated cells gain MDR. Because they
constitutively activate Nrf2, these de-differentiated cells constitu-
tively express antioxidant enzymes and drug efflux pumps.
Remarkably, in this setting, Nrf2 is not activated by oxidation,
but rather through a previously reported mechanism involving its
phosphorylation by PERK [42]. This finding is of particular
interest given Nrf2’s known role in promoting chemotherapy
survival [34] and its constitutive activation by mutation in a subset
of tumors [52–54]. Our findings indicate that a change in cellular
state, in the absence of mutation or oxidative stress, can also lead
to constitutive Nrf2 activation. This enables de-differentiated cells
to survive chemotherapy by preventing cellular damage before it
occurs. In contrast, differentiated cells activate Nrf2 only after
proteins and DNA have been oxidized. Although this defensive
response may succeed in neutralizing toxins, the damage to
cellular components would have already occurred.
Our findings also highlight the importance of stress signaling in
cancer. Cancer cells activate stress response pathways to protect
themselves from harsh environments encountered during tumor
growth and metastasis—for example, hypoxia and nutrient
deprivation—and also during the course of chemotherapy. We
show that de-differentiated tumor cells preactivate PERK-Nrf2
signaling in the absence of stress and that inhibition of PERK
sensitizes these cells to chemotherapy. These observations
complement prior studies establishing a role for the UPR and its
downstream targets in chemosensitization [55–67]. Collectively,
our findings provide mechanistic insights into how cellular de-
differentiation promotes MDR and suggest that inhibiting PERK-
Nrf2 signaling may reverse the MDR of cancer cells that are
otherwise drug resistant.
Materials and Methods
Ethics Statement
This study was performed in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
protocol was approved by the Animal Care and Use Committee of
the Massachusetts Institute of Technology (Protocol No. 0611-
071-14). All surgery was performed under isoflurane anesthesia,
and every effort was made to minimize suffering.
Cell Lines and Reagents
HMLE-shGFP and HMLE-Twist cell lines were a kind gift of
Dr. Robert Weinberg and cultured as described previously [8].
Basal breast cancer (MDA.MB.231, Hs578t) and luminal breast
cancer (MCF7, T47D, MDA.MB.361) cell lines were purchased
from ATCC and cultured in DMEM+10% FBS. The SUM159
basal breast cancer cell line was purchased from Asterand and
cultured in Ham’s F-12+5% FBS, Insulin and Hydrocortisone.
Chemical oxidizer menadione, Nrf2 activator oltipraz, and ER-
stress inducer thapsigargin were purchased from Sigma-Aldrich.
Cumene hydroperoxide (CH) was purchased from Life Technol-
ogies. The PERK inhibitor (PERKi) was described previously and
purchased from EMD Millipore [44]. Lentiviral short hairpin
RNA (shRNA) constructs were generated as described previously
[68]. Lentiviral integration was selected with 1 mg/ml puromycin
or 10 mg/ml blasticidin for 7 d, and knockdown efficiency was
measured by quantitative RT-PCR.
ROS Assays
ROS production was measured by fluorescent imaging or flow
cytometry analysis of MitoSOX or CellROX probes (Life
Technologies) according to manufacturer instructions. Lipid
peroxidation was assessed using the Click-iT Lipid Peroxidation
Imaging Kit (Life Technologies) according to the manufacturer
instructions. Total, reduced, and oxidized glutathione were
determined using the GSH/GSSG-GloTM Assay (Promega)
according to manufacturer instructions.
Efflux Assays
MDR1 efflux ability was measured by flow cytometry quanti-
fication of DiOC2(3)-dye efflux (EMD Millipore). Efflux assays
were conducted according to manufacturer instructions. Briefly,
cells were loaded with DiOC2(3)-dye for 10 min and either kept
on ice or placed at 37uC for 1.5 h to allow efflux of the dye.
Control and efflux samples were then immediately analyzed by
flow cytometry.
Western Blot
Cells were lysed with cold RIPA buffer plus complete protease
inhibitor cocktail (Roche Applied Science). The signal was
detected using the SuperSignal ECL system (Thermo Scientific).
The following antibodies were used for immunoblotting: SOD1
and Nrf2 (Santa Cruz Biotechnology) and CAT, HMOX-1, pan-
phospho, and b-actin (Cell Signaling Technologies).
Immunoprecipitation
HMLE-Twist cells grown in the presence or absence of 1 mM
PERK inhibitor for 48 h were lysed in nondenaturing lysis buffer
(20 mM Tris pH 7.5, 150 mM NaCl, 2 mM EDTA, 1% NP-40,
supplemented with cocktails for phosphatase and protease
inhibition). Equal protein amounts were used for immunoprecip-
controls. (g) Quantitative RT-PCR analysis of Nrf2 gene expression in cells stably expressing control (shLuc) of Nrf2-specific shRNA (shNrf2 1 and
shNrf2 2). Expression is shown normalized to the HMLE-Twist shLuc sample. (h and i) Fraction of control or Nrf2 knockdown cells surviving 30 nM Dox
(h) or 2 nM Tax (i) following pretreatment with 1 mM PERKi or DMSO and rescue with 25 mM Oltipraz, normalized to individual vehicle-treated
controls. *p,0.05. Data are presented as mean 6 SEM.
doi:10.1371/journal.pbio.1001945.g004
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Figure 5. PERK promotes chemotherapy resistance in vivo and correlates with tumor de-differentiation in patient samples. (a)
MDA.MB.231 cells were injected bilaterally into the mammary fat pads of female NOD/SCID mice. After reaching 60–80 mm3, tumors were treated
with PERKi (7.5 mg/kg/tumor) or DMSO by intratumoral injection, and Dox (2.5 mg/kg) or PBS by intraperitoneal (IP) injection according to the
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itation using PERK or Nrf2 antibody as per the vendors’
instructions. Samples were analyzed by immunoblotting using
antibodies to Nrf2 and phospho-Ser/Thr–containing proteins.
Immunofluorescence
Anti-Nrf2 (C-2) and anti–phospho-PERK (pPERK) antibodies
was purchased from Santa Cruz Biotechnology. Cells were fixed
on glass chamber slides in 4% PFA for 5 min, blocked with 5%
BSA in PBS, and incubated with primary antibody at a 1:50
dilution for 2 h. Slides were then washed with PBS and incubated
with an Alexa Fluor 488 anti-rabbit secondary antibody. The
nuclei were then stained with DAPI prior to analysis.
Immunohistochemistry
Immediately after harvest, tumors were fixed in 4% PFA for
24 h and paraffin-embedded. For staining, slides were deparaffi-
nized in xylene and then rehydrated with ethanol and double
distilled water. Hydrogen peroxide was used to block nonspecific
sites, and Diva Decloaker (BioCare Medical) solution and
microwaving were used for antigen retrieval. Sections were
incubated for 2 h at room temperature with a SOD1 antibody
(Santa Cruz Biotechnology). Expression was detected using HRP
anti-rabbit secondary antibody (BioCare Medical) and betazoid
DAB (BioCare Medical). The slides were counterstained with
hematoxylin.
Microarray Analysis
HMLE-shGFP and HMLE-Twist cells were treated with 1 mM
of PERKi or DMSO for 48 h and then treated with 40 mM
menadione or DMSO for 2 h immediately before RNA extrac-
tion. Total RNA were extracted using Qiagen RNeasy kit, and
integrity and quality verified prior to analysis. Gene expression
analyses were conducted using Affymetrix GeneChip Human
Genome U133 Plus 2.0 Arrays according to standard Affymetrix
protocols, with normalization as described previously [69].
Alteration of gene expression by PERKi and/or menadione was
calculated by comparing the expression of each gene across
treatment groups for each cell type. The gene-expression data
have been deposited in the NCBI Gene Expression Omnibus
public database (GEO; GSE59780).
Cell Survival Experiments
Cells were seeded and treated according to the schedule
described in Figure 4a. Briefly, cells were seeded on day 0,
pretreated with PERKi (1 mM) or DMSO for 48 h on days 1–3,
and rescued with NAC (3 mM), oltipraz (25 mM), or DMSO for
24 h on day 3. Cells were then treated with Dox (30 nM), Tax
(2 nM), or DMSO on day 4. Cells were followed for an additional
5 d, with complete media and drug replacement on day 7. Cell
survival was assessed on day 9 by manual cell count and
normalized as described for each experiment.
Animal Experiments
Female NOD/SCID mice were purchased from Jackson Labs.
The Animal Care and Use Committee of the Massachusetts
Institute of Technology approved all animal procedures. For
tumor regression studies, 16106 cells were injected bilaterally into
the mammary fat pad of 6–8-wk-old female NOD/SCID mice.
After reaching 60–80 mm3, tumors were treated with PERKi
(7.5 mg/kg/tumor) or DMSO by intratumoral injection on days 1,
2, 4, 5, 8, 9, 11, and 12, and Dox (2.5 mg/kg) or PBS by
intraperitoneal (IP) injection on days 2, 5, 9, and 12 unless
otherwise specified. Tumor volume over time and average tumor
weight at sacrifice were measured and presented as the average 6
standard error of mean for 10 tumors per treatment group.
Correlation Analysis of Gene Expression for Human
Cancer Samples
For correlation analyses, the PERK gene expression signature
was defined as the top 500 genes down-regulated in de-
differentiated cells treated with 1 mM PERKi for 48 h. The
PERK signature scores were calculated for each patient sample
from human breast cancer (GSE3143, GSE41998) and glioma
(GSE4412) datasets by summing the log-transformed normalized
expression values for each probe in the signature set. High- and
low-PERK signature groups were defined as the top or bottom
15% of samples within each group. Spearman’s rho was used to
measure correlation, and a p value was determined by Monte
Carlo sampling as described previously [43].
Statistical Analysis
All data are presented as mean 6 standard error of mean unless
otherwise specified. Student t test (two-tailed) was used to calculate
p values, and p,0.05 was considered significant.
Supporting Information
Table S1 Normalized gene expression data.
(XLSX)
Table S2 Genes differentially expressed between
HMLE-Twist and HMLE-shGFP cells.
(XLSX)
Table S3 ROS and efflux-related genes up-regulated in
HMLE-Twist compared to HMLE-shGFP cells.
(XLSX)
schedule described in Materials and Methods. Tumor volume over time with images of representative tumors is shown. (b) Formalin-fixed paraffin-
embedded tumor sections were stained for SOD1, and nuclei were counterstained with hematoxylin. Representative images are shown for each
treatment group. (c) Ratio of necrotic to live cells per tumor, presented as the average across tumors for each group. (d) SUM159 cells were injected
as above and tumor growth was monitored. The treatment schedule was modified to reduce the frequency of treatments to days 1, 2, 8, and 9.
Tumor volume over time with images of representative tumors is shown. (e) Relative amount of reduced glutathione (GSH) per tumor for each
treatment group, shown normalized to the mock treatment group. (f) MCF7 or T47D cells were injected as above and tumor growth was monitored.
The treatment schedule was modified to reduce the frequency of treatments to days 1, 2, 8, and 9. Tumor volume over time is shown. (g) Correlation
analyses of PERK pathway genes or IRE1 pathway genes and genes up-regulated in basal compared to luminal breast tumors. Analyses were
performed for two primary breast tumor datasets (GSE3143, n= 158; GSE41998, n=255). Spearman’s rho (Rho) was used to measure correlation. (h)
Fraction of PERK-high and PERK-low primary breast tumors showing complete response, partial response, or stable/progressive disease upon
treatment with standard AC regimen plus paclitaxel. (i) Scatter dot plot depicting the distribution of PERK-high and PERK-low primary human glioma
tumors classified as grade 3 or grade 4. Line represents mean 6 SEM. (j) Kaplan-Meier plots of distant metastasis-free survival of glioma patients.
Patient groups were separated based on PERK-high or PERK-low signature expression and shown compared to overall survival. The Mantel-Cox test
was utilized to determine the significance of the survival difference between PERK-high and PERK-low patient groups. *p,0.05. Data are presented as
mean 6 SEM.
doi:10.1371/journal.pbio.1001945.g005
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Table S4 Genes up-regulated upon treatment with
menadione.
(XLSX)
Table S5 ROS-responsive genes pre-activated in
HMLE-Twist cells.
(XLSX)
Table S6 Differentially expressed Nrf2 target genes.
(XLSX)
Acknowledgments
We thank Wendy Salmon in the Whitehead Keck Imaging Facility and
Patty Wisniewski in the Whitehead Flow Cytometry Facility for assistance
with data collection and interpretation.
Author Contributions
The author(s) have made the following declarations about their
contributions: Conceived and designed the experiments: CAD PBG.
Performed the experiments: CAD YF ESS EJT SS FR. Analyzed the data:
CAD YF ESS EJT SS. Contributed reagents/materials/analysis tools: YF
ESS. Wrote the paper: CAD PBG.
References
1. Gottesman MM (1993) How cancer cells evade chemotherapy: sixteenth
Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 53: 747–
754.
2. Simon SM, Schindler M (1994) Cell biological mechanisms of multidrug
resistance in tumors. Proc Natl Acad Sci U S A 91: 3497–3504.
3. Choi CH (2005) ABC transporters as multidrug resistance mechanisms and the
development of chemosensitizers for their reversal. Cancer Cell Int 5: 30.
4. Lobo NA, Shimono Y, Qian D, Clarke MF (2007) The biology of cancer stem
cells. Annu Rev Cell Dev Biol 23: 675–699.
5. Reya T, Morrison SJ, Clarke MF, Weissman IL (2001) Stem cells, cancer, and
cancer stem cells. Nature 414: 105–111.
6. Stingl J, Caldas C (2007) Molecular heterogeneity of breast carcinomas and the
cancer stem cell hypothesis. Nat Rev Cancer 7: 791–799.
7. Thiery JP (2002) Epithelial-mesenchymal transitions in tumour progression. Nat
Rev Cancer 2: 442–454.
8. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, et al. (2008) The epithelial-
mesenchymal transition generates cells with properties of stem cells. Cell 133:
704–715.
9. Morel AP, Lievre M, Thomas C, Hinkal G, Ansieau S, et al. (2008) Generation
of breast cancer stem cells through epithelial-mesenchymal transition. PLoS
ONE 3: e2888.
10. Aigner K, Dampier B, Descovich L, Mikula M, Sultan A, et al. (2007) The
transcription factor ZEB1 (deltaEF1) promotes tumour cell dedifferentiation by
repressing master regulators of epithelial polarity. Oncogene 26: 6979–6988.
11. Debeb BG, Lacerda L, Xu W, Larson R, Solley T, et al. (2012) Histone
deacetylase inhibitors stimulate dedifferentiation of human breast cancer cells
through WNT/beta-catenin signaling. Stem Cells 30: 2366–2377.
12. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, et al. (2013)
SOX2 promotes dedifferentiation and imparts stem cell-like features to
pancreatic cancer cells. Oncogenesis 2: e61.
13. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, et al. (2011) Paracrine
and autocrine signals induce and maintain mesenchymal and stem cell states in
the breast. Cell 145: 926–940.
14. Schwitalla S, Fingerle AA, Cammareri P, Nebelsiek T, Goktuna SI, et al. (2013)
Intestinal tumorigenesis initiated by dedifferentiation and acquisition of stem-
cell-like properties. Cell 152: 25–38.
15. Saxena M, Stephens MA, Pathak H, Rangarajan A (2011) Transcription factors
that mediate epithelial-mesenchymal transition lead to multidrug resistance by
upregulating ABC transporters. Cell Death Dis 2: e179.
16. Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an
emerging axis of evil in the war on cancer. Oncogene 29: 4741–4751.
17. Gammon L, Biddle A, Heywood HK, Johannessen AC, Mackenzie IC (2013)
Sub-sets of cancer stem cells differ intrinsically in their patterns of oxygen
metabolism. PLoS ONE 8: e62493.
18. Diehn M, Cho RW, Lobo NA, Kalisky T, Dorie MJ, et al. (2009) Association of
reactive oxygen species levels and radioresistance in cancer stem cells. Nature
458: 780–783.
19. Dean M, Fojo T, Bates S (2005) Tumour stem cells and drug resistance. Nat Rev
Cancer 5: 275–284.
20. Azzi S, Bruno S, Giron-Michel J, Clay D, Devocelle A, et al. (2011)
Differentiation therapy: targeting human renal cancer stem cells with interleukin
15. J Natl Cancer Inst 103: 1884–1898.
21. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, et al. (2010)
Differentiation therapy exerts antitumor effects on stem-like glioma cells. Clin
Cancer Res 16: 2715–2728.
22. Grimwade D, Mistry AR, Solomon E, Guidez F (2010) Acute promyelocytic
leukemia: a paradigm for differentiation therapy. Cancer Treat Res 145: 219–
235.
23. Ohno R, Asou N, Ohnishi K (2003) Treatment of acute promyelocytic leukemia:
strategy toward further increase of cure rate. Leukemia 17: 1454–1463.
24. Elenbaas B, Spirio L, Koerner F, Fleming MD, Zimonjic DB, et al. (2001)
Human breast cancer cells generated by oncogenic transformation of primary
mammary epithelial cells. Genes Dev 15: 50–65.
25. Yang J, Mani SA, Donaher JL, Ramaswamy S, Itzykson RA, et al. (2004) Twist,
a master regulator of morphogenesis, plays an essential role in tumor metastasis.
Cell 117: 927–939.
26. Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, et al.
(2009) Epithelial to mesenchymal transition contributes to drug resistance in
pancreatic cancer. Cancer Res 69: 5820–5828.
27. Li QQ, Xu JD, Wang WJ, Cao XX, Chen Q, et al. (2009) Twist1-mediated
adriamycin-induced epithelial-mesenchymal transition relates to multidrug
resistance and invasive potential in breast cancer cells. Clin Cancer Res 15:
2657–2665.
28. Loor G, Kondapalli J, Schriewer JM, Chandel NS, Vanden Hoek TL, et al.
(2010) Menadione triggers cell death through ROS-dependent mechanisms
involving PARP activation without requiring apoptosis. Free Radic Biol Med 49:
1925–1936.
29. Alam J, Stewart D, Touchard C, Boinapally S, Choi AM, et al. (1999) Nrf2, a
Cap’n’Collar transcription factor, regulates induction of the heme oxygenase-1
gene. J Biol Chem 274: 26071–26078.
30. Alam J, Wicks C, Stewart D, Gong P, Touchard C, et al. (2000) Mechanism of
heme oxygenase-1 gene activation by cadmium in MCF-7 mammary epithelial
cells. Role of p38 kinase and Nrf2 transcription factor. J Biol Chem 275: 27694–
27702.
31. Maines MD (1988) Heme oxygenase: function, multiplicity, regulatory
mechanisms, and clinical applications. FASEB J 2: 2557–2568.
32. Itoh K, Chiba T, Takahashi S, Ishii T, Igarashi K, et al. (1997) An Nrf2/small
Maf heterodimer mediates the induction of phase II detoxifying enzyme genes
through antioxidant response elements. Biochem Biophys Res Commun 236:
313–322.
33. Osburn WO, Kensler TW (2008) Nrf2 signaling: an adaptive response pathway
for protection against environmental toxic insults. Mutat Res 659: 31–39.
34. Wang XJ, Sun Z, Villeneuve NF, Zhang S, Zhao F, et al. (2008) Nrf2 enhances
resistance of cancer cells to chemotherapeutic drugs, the dark side of Nrf2.
Carcinogenesis 29: 1235–1243.
35. McMahon M, Itoh K, Yamamoto M, Chanas SA, Henderson CJ, et al. (2001)
The Cap’n’Collar basic leucine zipper transcription factor Nrf2 (NF-E2 p45-
related factor 2) controls both constitutive and inducible expression of intestinal
detoxification and glutathione biosynthetic enzymes. Cancer Res 61: 3299–
3307.
36. Malhotra D, Portales-Casamar E, Singh A, Srivastava S, Arenillas D, et al.
(2010) Global mapping of binding sites for Nrf2 identifies novel targets in cell
survival response through ChIP-Seq profiling and network analysis. Nucleic
Acids Res 38: 5718–5734.
37. Ichimura Y, Waguri S, Sou YS, Kageyama S, Hasegawa J, et al. (2013)
Phosphorylation of p62 activates the Keap1-Nrf2 pathway during selective
autophagy. Mol Cell 51: 618–631.
38. Huang HC, Nguyen T, Pickett CB (2002) Phosphorylation of Nrf2 at Ser-40 by
protein kinase C regulates antioxidant response element-mediated transcription.
J Biol Chem 277: 42769–42774.
39. Lee JM, Hanson JM, Chu WA, Johnson JA (2001) Phosphatidylinositol 3-kinase,
not extracellular signal-regulated kinase, regulates activation of the antioxidant-
responsive element in IMR-32 human neuroblastoma cells. J Biol Chem 276:
20011–20016.
40. Shi Y, Vattem KM, Sood R, An J, Liang J, et al. (1998) Identification and
characterization of pancreatic eukaryotic initiation factor 2 alpha-subunit kinase,
PEK, involved in translational control. Molecular and cellular biology 18: 7499–
7509.
41. Harding HP, Zhang Y, Ron D (1999) Protein translation and folding are
coupled by an endoplasmic-reticulum-resident kinase. Nature 397: 271–274.
42. Cullinan SB, Zhang D, Hannink M, Arvisais E, Kaufman RJ, et al. (2003) Nrf2
is a direct PERK substrate and effector of PERK-dependent cell survival.
Molecular and cellular biology 23: 7198–7209.
43. Feng YX, Sokol ES, Del Vecchio CA, Sanduja S, Claessen JH, et al. (2014)
Epithelial-to-Mesenchymal Transition Activates PERK-eIF2alpha and Sensitiz-
es Cells to Endoplasmic Reticulum Stress. Cancer Discov.
44. Axten JM, Medina JR, Feng Y, Shu A, Romeril SP, et al. (2012) Discovery of 7-
methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1H-indol-5-yl)-7H-
p yrrolo[2,3-d]pyrimidin-4-amine (GSK2606414), a potent and selective first-in-
class inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase
(PERK). Journal of medicinal chemistry 55: 7193–7207.
PERK-Nrf2 Signaling Confers Multidrug Resistance
PLOS Biology | www.plosbiology.org 11 September 2014 | Volume 12 | Issue 9 | e1001945
45. Blick T, Widodo E, Hugo H, Waltham M, Lenburg ME, et al. (2008) Epithelial
mesenchymal transition traits in human breast cancer cell lines. Clin Exp
Metastasis 25: 629–642.
46. Zafarullah M, Li WQ, Sylvester J, Ahmad M (2003) Molecular mechanisms of
N-acetylcysteine actions. Cell Mol Life Sci 60: 6–20.
47. Ramos-Gomez M, Kwak MK, Dolan PM, Itoh K, Yamamoto M, et al. (2001)
Sensitivity to carcinogenesis is increased and chemoprotective efficacy of enzyme
inducers is lost in nrf2 transcription factor-deficient mice. Proc Natl Acad
Sci U S A 98: 3410–3415.
48. Blais JD, Addison CL, Edge R, Falls T, Zhao H, et al. (2006) Perk-dependent
translational regulation promotes tumor cell adaptation and angiogenesis in
response to hypoxic stress. Mol Cell Biol 26: 9517–9532.
49. Wang Y, Alam GN, Ning Y, Visioli F, Dong Z, et al. (2012) The unfolded
protein response induces the angiogenic switch in human tumor cells through
the PERK/ATF4 pathway. Cancer Res 72: 5396–5406.
50. Atkins C, Liu Q, Minthorn E, Zhang SY, Figueroa DJ, et al. (2013)
Characterization of a novel PERK kinase inhibitor with antitumor and
antiangiogenic activity. Cancer Res 73: 1993–2002.
51. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, et al. (2006)
Gene expression profiling of breast cell lines identifies potential new basal
markers. Oncogene 25: 2273–2284.
52. Kim YR, Oh JE, Kim MS, Kang MR, Park SW, et al. (2010) Oncogenic NRF2
mutations in squamous cell carcinomas of oesophagus and skin. J Pathol 220:
446–451.
53. Shibata T, Kokubu A, Gotoh M, Ojima H, Ohta T, et al. (2008) Genetic
alteration of Keap1 confers constitutive Nrf2 activation and resistance to
chemotherapy in gallbladder cancer. Gastroenterology 135: 1358–1368, 1368
e1351–1354.
54. Singh A, Misra V, Thimmulappa RK, Lee H, Ames S, et al. (2006)
Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS
Med 3: e420.
55. Mann MJ, Hendershot LM (2006) UPR activation alters chemosensitivity of
tumor cells. Cancer Biol Ther 5: 736–740.
56. Chatterjee S, Hirota H, Belfi CA, Berger SJ, Berger NA (1997) Hypersensitivity
to DNA cross-linking agents associated with up-regulation of glucose-regulated
stress protein GRP78. Cancer Res 57: 5112–5116.
57. Jiang CC, Mao ZG, Avery-Kiejda KA, Wade M, Hersey P, et al. (2009)
Glucose-regulated protein 78 antagonizes cisplatin and adriamycin in human
melanoma cells. Carcinogenesis 30: 197–204.
58. Reddy RK, Mao C, Baumeister P, Austin RC, Kaufman RJ, et al. (2003)
Endoplasmic reticulum chaperone protein GRP78 protects cells from apoptosis
induced by topoisomerase inhibitors: role of ATP binding site in suppression of
caspase-7 activation. J Biol Chem 278: 20915–20924.
59. Gray MD, Mann M, Nitiss JL, Hendershot LM (2005) Activation of the
unfolded protein response is necessary and sufficient for reducing topoisomerase
IIalpha protein levels and decreasing sensitivity to topoisomerase-targeted drugs.
Mol Pharmacol 68: 1699–1707.
60. Mandic A, Hansson J, Linder S, Shoshan MC (2003) Cisplatin induces
endoplasmic reticulum stress and nucleus-independent apoptotic signaling.
J Biol Chem 278: 9100–9106.
61. Ledoux S, Yang R, Friedlander G, Laouari D (2003) Glucose depletion
enhances P-glycoprotein expression in hepatoma cells: role of endoplasmic
reticulum stress response. Cancer Res 63: 7284–7290.
62. Bentires-Alj M, Barbu V, Fillet M, Chariot A, Relic B, et al. (2003) NF-kappaB
transcription factor induces drug resistance through MDR1 expression in cancer
cells. Oncogene 22: 90–97.
63. Boller YC, Brandes LM, Russell RL, Lin ZP, Patierno SR, et al. (2000)
Prostaglandin A1 inhibits stress-induced NF-kappaB activation and reverses
resistance to topoisomerase II inhibitors. Oncol Res 12: 383–395.
64. Brandes LM, Lin ZP, Patierno SR, Kennedy KA (2001) Reversal of
physiological stress-induced resistance to topoisomerase II inhibitors using an
inducible phosphorylation site-deficient mutant of I kappa B alpha. Mol
Pharmacol 60: 559–567.
65. Hughes CS, Shen JW, Subjeck JR (1989) Resistance to etoposide induced by
three glucose-regulated stresses in Chinese hamster ovary cells. Cancer Res 49:
4452–4454.
66. Mann MJ, Pereira ER, Liao N, Hendershot LM (2012) UPR-induced resistance
to etoposide is downstream of PERK and independent of changes in
topoisomerase IIalpha levels. PLoS ONE 7: e47931.
67. Shen J, Hughes C, Chao C, Cai J, Bartels C, et al. (1987) Coinduction of
glucose-regulated proteins and doxorubicin resistance in Chinese hamster cells.
Proc Natl Acad Sci U S A 84: 3278–3282.
68. Gupta PB, Fillmore CM, Jiang G, Shapira SD, Tao K, et al. (2011) Stochastic
state transitions give rise to phenotypic equilibrium in populations of cancer
cells. Cell 146: 633–644.
69. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004)
Bioconductor: open software development for computational biology and
bioinformatics. Genome Biol 5: R80.
PERK-Nrf2 Signaling Confers Multidrug Resistance
PLOS Biology | www.plosbiology.org 12 September 2014 | Volume 12 | Issue 9 | e1001945
